Who should participate in clinical trials and who not? Can clinical trials be made more efficient and effective?

被引：1

作者：

Pritchard, Kathleen I. ^{[1
,2
]}

机构：

[1] Sunnybrook Hlth Sci Ctr, Sunnybrook Odette Canc Ctr, Toronto, ON M4N 3M5, Canada

[2] Univ Toronto, Toronto, ON M4N 3M5, Canada

来源：

BREAST CANCER RESEARCH | 2008年 / 10卷 / Suppl 4期

关键词：

D O I：

10.1186/bcr2183

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页数：3

共 4 条

[1]

FORNANDER T, 1989, LANCET, V1, P616

[2] A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer [J].

Goss, PE ;

Ingle, JN ;

Martino, S ;

Robert, NJ ;

Muss, HB ;

Piccart, MJ ;

Castiglione, M ;

Tu, D ;

Shepherd, LE ;

Pritchard, KI ;

Livingston, RB ;

Davidson, NE ;

Norton, L ;

Perez, EA ;

Abrams, JS ;

Therasse, P ;

Palmer, MJ ;

Pater, JL .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (19) :1793-1802

[3] Coronary heart disease mortality after 5 years of adjuvant tamoxifen therapy:: Results from a randomized trial [J].

Nordenskjöld, B ;

Rosell, J ;

Rutqvist, LE ;

Malmström, PO ;

Bergh, J ;

Bengtsson, NO ;

Hatschek, T ;

Wallgren, A ;

Carstensen, J .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (21) :1609-1610

[4]

*WHO, GOOD CLIN PRACT HDB

← 1 →